Primary Recommendation

Clinigen - New issue growing like topsy

November 2012

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Signs are mounting that the dull period is well and truly over for small caps with the shares of so many companies featured in Sharewatch hitting new highs; however, as we often say, the winners that dominate a new bull market will not necessarily be the same that dominated time out but will include new names. One company that we think is going to spectacularly catch the imagination of investors is Clinigen, a pharmaceutical business, which joined AIM on 25 September. Over the past three years to end 30 June, the group's sales have already grown four-fold from £21.3m in 2009 to £82.1m in 2012. Pretax profit has lifted almost nine-fold from £1.22m to £10.25m in that time but ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Findel -Prospective PE of 6.2

Judges Scientific - WH Ireland sets 950p share price target

Clinigen (November 2016)

Clinigen (October 2016)

Clinigen (October 2015)

Clinigen (August 2015)

Clinigen - Completes £225m Idis acquisition (June 2015)

Clinigen (April 2015)

Clinigen (February 2015)

Clinigen - Acquires speciality products (September 2014)

Clinigen - Company reassures investors with trading update (August 2014)

Clinigen (March 2014)

Clinigen - Growing rapidly into valuation (February 2014)

Clinigen - On lookout for 3-5 more deals (November 2013)

Clinigen - Another upgrade to forecast (September 2013)

Clinigen - First of half a dozen deals (April 2013)

Clinigen - Acquisition anticipated in March (March 2013)

Clinigen - Trial services to grow at 17% annual clip (December 2012)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X